$IRD News

Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness

FDA Clears Opus Genetics’ IND Application For Opgx-RDH12, Investigational Gene Therapy For Treatment Of RDH12-Associated Leber Congenital Amaurosis

Opus Genetics Receives FDA Approval For Its Supplemental New Drug Application For Phentolamine Ophthalmic Solution 0.75% To Treat Presbyopia In Adults

Citizens Reiterates Market Outperform on Opus Genetics, Maintains $17 Price Target

Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026

Opus Genetics Presents Clinical Findings From OPGx-BEST1 And OPGx-LCA5 Gene Therapy Programs At Retina In Rio 2026; Phase 3 Clinical Trial Dosing For OPGx-LCA5 Expected In Q4 Of 2026

Opus Genetics to Present at the Chardan Annual Healthcare Conference

Jones Trading Maintains Buy on Opus Genetics, Raises Price Target to $17

Opus Genetics, Inc. (IRD) Presents at Euretina 2026 - Slideshow

Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?

Opus Genetics: A Resounding Study Success Merits A Higher Valuation

Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript

Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13

IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial

Oppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20

Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial - Slideshow

Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data, Targets Potential Phase 3 Dosing in 2027

HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target

BTIG Reiterates Buy on Opus Genetics, Maintains $12 Price Target

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027